Evaluation of the Safety and Preliminary Efficacy of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) in Patients for Ischemic Stroke
Ischemic Stroke
Age 18-70 years, no gender restriction
Confirmed anterior circulation occlusion by CTA or MR angiography (MRA)
Pre-stroke mRS score of 0-1
Intracranial hemorrhagic conditions observed on cranial CT: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation, etc.
Known severe allergy to contrast agents (excluding mild rash-type allergies)
Known bleeding tendencies (including but not limited to): platelet count < 100×10^9/L; received heparin treatment within 48 hours with aPTT >= 35s; currently taking warfarin with INR > 1.7
Patients with brain tumors, or a history of epilepsy and severe head trauma